Literature DB >> 11902733

Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia?

Alan S Gamis1, Joanne M Hilden.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11902733     DOI： 10.1097/00043426-200201000-00002

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


× No keyword cloud information.
  5 in total

1.  Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.

Authors:  Hiroto Inaba; Margherita Londero; Scott H Maurer; Mihaela Onciu; Yubin Ge; Jeffrey W Taub; Jeffrey E Rubnitz; Susana C Raimondi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 2.  Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

Authors:  Laurence Rozen; Sophie Huybrechts; Laurence Dedeken; Catherine Heijmans; Barbara Dessars; Pierre Heimann; Frédéric Lambert; Denis F Noubouossie; Alina Ferster; Anne Demulder
Journal:  Eur J Pediatr       Date:  2013-11-20       Impact factor: 3.183

3.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

Review 4.  Acute Leukemia in Infants.

Authors:  Azada Ibrahimova; Lauren Pommert; Erin H Breese
Journal:  Curr Oncol Rep       Date:  2021-02-12       Impact factor: 5.075

Review 5.  Acute Megakaryocytic Leukemia.

Authors:  Maureen McNulty; John D Crispino
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.